Therefore, we hypothesized that Curcumin could enhance the anti-tumor effects of Lenvatinib as a tyrosine kinase inhibitor, and that its anti-EGFR potential could help overcome the Lenvatinib resistance in HCC. Here, EGFR is linked to neoplasm.